This company has been acquired
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Science 37 Holdings Gelecekteki Büyüme
Future kriter kontrolleri 1/6
Science 37 Holdings is forecast to grow earnings and revenue by 66.7% and 17.5% per annum respectively while EPS is expected to grow by 67.9% per annum.
Anahtar bilgiler
66.7%
Kazanç büyüme oranı
67.9%
EPS büyüme oranı
| Life Sciences kazanç büyümesi | 17.5% |
| Gelir büyüme oranı | 17.5% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 30 Jan 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Science 37 Holdings, Inc. (NASDAQ:SNCE) Might Not Be As Mispriced As It Looks
Dec 18
Investors Continue Waiting On Sidelines For Science 37 Holdings, Inc. (NASDAQ:SNCE)
Apr 17Science 37, Syapse team for faster patient enrollment in cancer trials
Aug 18Science 37 reports Q2 mixed earnings; narrows FY22 guidance
Aug 11Results: Science 37 Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
May 13Science 37 Holdings (NASDAQ:SNCE) Is In A Good Position To Deliver On Growth Plans
Apr 11Science 37: Pioneering Decentralized Clinical Trials
Jan 02We Think Science 37 Holdings (NASDAQ:SNCE) Can Afford To Drive Business Growth
Nov 04Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 95 | 3 | -18 | 30 | 3 |
| 12/31/2025 | 75 | -25 | -28 | 3 | 3 |
| 12/31/2024 | 63 | -38 | -44 | -9 | 4 |
| 12/31/2023 | 58 | -73 | -81 | -46 | 4 |
| 9/30/2023 | 60 | -125 | -74 | -48 | N/A |
| 6/30/2023 | 62 | -134 | -84 | -58 | N/A |
| 3/31/2023 | 66 | -121 | -98 | -67 | N/A |
| 12/31/2022 | 70 | -51 | -107 | -75 | N/A |
| 9/30/2022 | 75 | -50 | -115 | -82 | N/A |
| 6/30/2022 | 73 | -41 | -108 | -78 | N/A |
| 3/31/2022 | 66 | -43 | -83 | -57 | N/A |
| 12/31/2021 | 60 | -94 | -57 | -36 | N/A |
| 9/30/2021 | 50 | -42 | -37 | -23 | N/A |
| 6/30/2021 | 43 | -35 | -33 | -23 | N/A |
| 3/31/2021 | 33 | -33 | -33 | -26 | N/A |
| 12/31/2020 | 24 | -32 | -32 | -25 | N/A |
| 12/31/2019 | 14 | -18 | -20 | -16 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: SNCE is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: SNCE is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: SNCE is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: SNCE's revenue (17.5% per year) is forecast to grow faster than the US market (8.1% per year).
Yüksek Büyüme Geliri: SNCE's revenue (17.5% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if SNCE's Return on Equity is forecast to be high in 3 years time